Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib Real-World Study in Chinese ES-SCLC
NCT05071703Phase 4Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of trilaciclib in myelosuppression, sponsored by Simcere Pharmaceutical Group. Started Aug 2021; status: completed.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT05071703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05071703.